These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 15280548)

  • 1. Pauling and Corey's alpha-pleated sheet structure may define the prefibrillar amyloidogenic intermediate in amyloid disease.
    Armen RS; DeMarco ML; Alonso DO; Daggett V
    Proc Natl Acad Sci U S A; 2004 Aug; 101(32):11622-7. PubMed ID: 15280548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anatomy of an amyloidogenic intermediate: conversion of beta-sheet to alpha-sheet structure in transthyretin at acidic pH.
    Armen RS; Alonso DO; Daggett V
    Structure; 2004 Oct; 12(10):1847-63. PubMed ID: 15458633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of two distinct beta2-microglobulin unfolding intermediates that may lead to amyloid fibrils of different morphology.
    Armen RS; Daggett V
    Biochemistry; 2005 Dec; 44(49):16098-107. PubMed ID: 16331970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.
    Lai Z; Colón W; Kelly JW
    Biochemistry; 1996 May; 35(20):6470-82. PubMed ID: 8639594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is polyproline II helix the killer conformation? A Raman optical activity study of the amyloidogenic prefibrillar intermediate of human lysozyme.
    Blanch EW; Morozova-Roche LA; Cochran DA; Doig AJ; Hecht L; Barron LD
    J Mol Biol; 2000 Aug; 301(2):553-63. PubMed ID: 10926527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localized structural fluctuations promote amyloidogenic conformations in transthyretin.
    Lim KH; Dyson HJ; Kelly JW; Wright PE
    J Mol Biol; 2013 Mar; 425(6):977-88. PubMed ID: 23318953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-sheet: The toxic conformer in amyloid diseases?
    Daggett V
    Acc Chem Res; 2006 Sep; 39(9):594-602. PubMed ID: 16981675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformational polymorphism of the amyloidogenic peptide homologous to residues 113-127 of the prion protein.
    Satheeshkumar KS; Jayakumar R
    Biophys J; 2003 Jul; 85(1):473-83. PubMed ID: 12829502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro.
    Colon W; Kelly JW
    Biochemistry; 1992 Sep; 31(36):8654-60. PubMed ID: 1390650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantum mechanical studies on model alpha-pleated sheets.
    Wu H; Canfield A; Adhikari J; Huo S
    J Comput Chem; 2010 Apr; 31(6):1216-23. PubMed ID: 19827141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial conformational changes of human transthyretin under partially denaturing conditions.
    Yang M; Lei M; Bruschweiler R; Huo S
    Biophys J; 2005 Jul; 89(1):433-43. PubMed ID: 15821170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different disease-causing mutations in transthyretin trigger the same conformational conversion.
    Steward RE; Armen RS; Daggett V
    Protein Eng Des Sel; 2008 Mar; 21(3):187-95. PubMed ID: 18276611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular dynamics simulations and free energy analyses on the dimer formation of an amyloidogenic heptapeptide from human beta2-microglobulin: implication for the protofibril structure.
    Lei H; Wu C; Wang Z; Duan Y
    J Mol Biol; 2006 Mar; 356(4):1049-63. PubMed ID: 16403526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.
    McCutchen SL; Lai Z; Miroy GJ; Kelly JW; Colón W
    Biochemistry; 1995 Oct; 34(41):13527-36. PubMed ID: 7577941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct observation of protein folding, aggregation, and a prion-like conformational conversion.
    Ding F; LaRocque JJ; Dokholyan NV
    J Biol Chem; 2005 Dec; 280(48):40235-40. PubMed ID: 16204250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure and aggregation mechanism of beta(2)-microglobulin (83-99) peptides studied by molecular dynamics simulations.
    Liang C; Derreumaux P; Wei G
    Biophys J; 2007 Nov; 93(10):3353-62. PubMed ID: 17693474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
    Lashuel HA; Lai Z; Kelly JW
    Biochemistry; 1998 Dec; 37(51):17851-64. PubMed ID: 9922152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural properties of an amyloid precursor of beta(2)-microglobulin.
    McParland VJ; Kalverda AP; Homans SW; Radford SE
    Nat Struct Biol; 2002 May; 9(5):326-31. PubMed ID: 11967566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimum amyloid fibril formation of a peptide fragment suggests the amyloidogenic preference of beta2-microglobulin under physiological conditions.
    Ohhashi Y; Hasegawa K; Naiki H; Goto Y
    J Biol Chem; 2004 Mar; 279(11):10814-21. PubMed ID: 14699107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Changes Associated with Transthyretin Misfolding and Amyloid Formation Revealed by Solution and Solid-State NMR.
    Lim KH; Dasari AK; Hung I; Gan Z; Kelly JW; Wemmer DE
    Biochemistry; 2016 Apr; 55(13):1941-4. PubMed ID: 26998642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.